Management of psoriasis in older adults may be influenced by the relative increased prevalence of comorbidities, immunosuppression, and use of multiple medications in this group. A recent review (Drugs Aging. 2020 Aug 10, online) confirms that biologic agents are well tolerated and are more effective than conventional systemic therapies and that new small-molecule agents, such as apremilast, offer an effective and safe treatment option for older patients with psoriasis.
The authors note that older patients with psoriasis are oftentimes underrepresented in the clinical trials for new medications. However, there are date from follow-up studies that have focused on the safety and efficacy of these medications in older adults. Nonetheless, despite demonstrated safety and efficacy of biologic agents, in elderly patients, they are used roughly half as often in this group, compared to non-elderly patients.